AVIR - Atea Pharmaceuticals, Inc.
IEX Last Trade
3.26
0.005 0.153%
Share volume: 6,517
Last Updated: Thu 26 Dec 2024 08:29:53 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$3.26
0.00
0.15%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
0.31%
1 Month
-1.52%
3 Months
-5.52%
6 Months
-3.56%
1 Year
2.20%
2 Year
-25.63%
Key data
Stock price
$3.26
DAY RANGE
$3.18 - $3.27
52 WEEK RANGE
$2.94 - $4.60
52 WEEK CHANGE
$4.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jean-Pierre Sommadossi
Region: US
Website: ateapharma.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ateapharma.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Atea Pharmaceuticals, Inc. focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trials for dengue; AT-777, an NS5A inhibitor, and AT-281, a pharmaceutically acceptable salt.
Recent news